Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has a beta value of 3.13 and has seen 2,358,543 shares traded in the last trading session. The company, currently valued at $157.19 Million, closed the last trade at $6.3 per share which meant it lost $0 on the day or -0.47% during that session. The ZYNE stock price is -149.21% off its 52-week high price of $15.7 and 59.52% above the 52-week low of $2.55. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.48 Million shares traded. The 3-month trading volume is 1.18 Million shares.

The consensus among analysts is that Zynerba Pharmaceuticals, Inc. (ZYNE) is a Buy stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 7 have rated it as a Hold, with 6 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.45.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) trade information

Despite being -0.47% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the ZYNE stock price touched $6.75-6 or saw a rise of 6.67%. Year-to-date, Zynerba Pharmaceuticals, Inc. shares have moved 4.3%, while the 5-day performance has seen it change 4.3%. Over the past 30 days, the shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) have changed 1.78%. Short interest in the company has seen 6.79 Million shares shorted with days to cover at 5.75.

Wall Street analysts have a consensus price target for the stock at $17.5, which means that the shares’ value could jump 177.78% from current levels. The projected low price target is $4.5 while the price target rests at a high of $26. In that case, then, we find that the current price level is +312.7% off the targeted high while a plunge would see the stock lose -28.57% from current levels.

Zynerba Pharmaceuticals, Inc. (ZYNE) estimates and forecasts

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -17.8% over the past 5 years. Earnings growth for 2020 is a modest +42.6% while over the next 5 years, the company’s earnings are expected to increase by 0%.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)’s Major holders

Insiders own 12.32% of the company shares, while shares held by institutions stand at 46.94% with a share float percentage of 53.54%. Investors are also buoyed by the number of investors in a company, with Zynerba Pharmaceuticals, Inc. having a total of 113 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 1.61 Million shares worth more than $6.16 Million. As of March 30, 2020, Vanguard Group, Inc. (The) held 6.45% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 1.51 Million shares as of March 30, 2020. The firm’s total holdings are worth over $5.78 Million and represent 6.05% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are ETF Managers Tr-EFTMG Alternative Harvest ETF and Vanguard Total Stock Market Index Fund. As of March 30, 2020, the former fund manager holds about 4.84% shares in the company for having 1208126 shares of worth $4.63 Million while later fund manager owns 630.14 Thousand shares of worth $2.41 Million as of March 30, 2020, which makes it owner of about 2.53% of company’s outstanding stock.